2nd SOHO Italian Conference

http://www.sohoitaly.it/

 

Leukemia
14:51

2nd SOHO Italian Conference

MRD & ALL Management: What Role Does It Play in AlloHSCT Setting?

FEATURING Alessandro Rambaldi
  • 26 views
  • February 2, 2021
17:00

2nd SOHO Italian Conference

How I Treat AML at MD Anderson: ATRA & GO Combos, Sequential HD Chemo Rx, Maintenance Azacitidine, Oral Decitabine/Cedazuridine, Alternating Low-Dose Chemo Rx, Venetoclax Dose Adjustments

FEATURING Hagop Kantarjian
  • 195 views
  • February 2, 2021
  • 1
09:43

2nd SOHO Italian Conference

MD Anderson Future Directions in AML: Efficacy of FLT3 / IDH Inhibitors and New Targeted Therapy Combos

FEATURING Hagop Kantarjian
  • 303 views
  • February 2, 2021
  • 3
10:02

2nd SOHO Italian Conference

How I Treat ALL at MD Anderson: What Hyper-CVAD Combinations Showed as the Most Effective?

FEATURING Hagop Kantarjian
  • 30 views
  • February 2, 2021
13:11

2nd SOHO Italian Conference

MD Anderson Future Directions in ALL: How Effective Are New Blina/Ino Combinations?

FEATURING Hagop Kantarjian
  • 17 views
  • February 2, 2021
13:38

2nd SOHO Italian Conference

TFR and CML: Why Is TFR Important? What Happens After? Why Is It Difficult to Suggest TFR to Patients?

FEATURING Elisabetta Abruzzese
  • 11 views
  • January 27, 2021
08:52

2nd SOHO Italian Conference

TFR in CML: What Are the Influencing Factors? Do Patients Lose MR After Stopping TKIs? Can We Predict the Probability of Maintaining the TFR?

FEATURING Michele Malagola
  • 12 views
  • January 27, 2021
14:09

2nd SOHO Italian Conference

How I Treat Frontline CML: What Are the Differences in ELTS vs. Sokal’s Risk Score? Does Imatinib OS Differ in High/Intermediate/Low-Risk Patients? Should We Discontinue TKIs in Some Groups?

FEATURING Giuseppe Saglio
  • 16 views
  • January 27, 2021
09:15

2nd SOHO Italian Conference

Post-SCT Maintenance in AML: What Is the Role of Hypomethylating Agents? Does FLT3-ITD Impact on the Outcome of Related & Unrelated SCT for Adults in 1st Remission? Does Sorafenib Improve OS/PFS?

FEATURING Alessandra Sperotto
  • 21 views
  • January 25, 2021
15:37

2nd SOHO Italian Conference

Allogenic Transplant in AML: How Does ASCT Compare to Chemo in Older Patients? Is FLT3i Sorafenib the Best Option for Post-Transplant Maintenance?

FEATURING Attilio Olivieri
  • 18 views
  • January 25, 2021
13:56

2nd SOHO Italian Conference

MRD Assessment in Frontline AML: What Are the Characteristics of Different Techniques? MRD Before and After ASCT - Who Benefits From the Treatment?

FEATURING Francesco Buccisano
  • 21 views
  • January 25, 2021
09:22

2nd SOHO Italian Conference

Prognostic Relevance of BPDCN-Like Phenotype in Newly Diagnosed AML: What Is It and How Does It Present? Does It Affect OS?

FEATURING Roberto Lemoli
  • 21 views
  • January 25, 2021
11:45

2nd SOHO Italian Conference

Pro-Apoptotic Pathways in AML: How Does Venetoclax Work in Combination With Different Inhibitors? Do Gilteritinib & Ato Increase Apoptosis?

FEATURING Sara Galimberti
  • 10 views
  • January 25, 2021
14:40

2nd SOHO Italian Conference

Genomic Sequencing in AML and MDS: How Can We Define Subtypes and Mutation Constellations With Prognostic Significance?

FEATURING Ilaria Iacobucci
  • 25 views
  • January 25, 2021
12:17

2nd SOHO Italian Conference

Novel mAbs in ALL: Is Ino Better than SoC? What Is the MRD-Negativity Rate? Can the Addition of Blina Help Achieve CR in Older Patients?

FEATURING Francesco Lanza
  • 11 views
  • January 25, 2021
10:44

2nd SOHO Italian Conference

mAbs in ALL: Does Blinatumomab Prolong Survival in R/R Ph+/- Disease? Who Can Advance to HSCT? Can Frontline Dasatinib+Blina Help Achieve MRD? What Is the ORR With Ino?

FEATURING Cristina Papayannidis
  • 11 views
  • January 25, 2021
08:04

2nd SOHO Italian Conference

Cell Morphology in Acute Leukemias & Hematologic Malignancies: Differences in Molecular/Genetic Lesions

FEATURING Gina Zini
  • 28 views
  • January 25, 2021
11:05

2nd SOHO Italian Conference

Synthetic Lethality Against ALL: How Often Is the Expression of DDR-Genes Altered and What Are the Key Genes Involved? Does Doxorubicin Induce Apoptosis?

FEATURING Andrea Ghelli Luserna Di Rora
  • 13 views
  • January 25, 2021
14:43

2nd SOHO Italian Conference

2020 SOHO Update on R/R ALL: Is CD19-Targeted CAR-T Beneficial for OS/ORR? What Are the Strategies to Improve Outcomes? Can We Use CD22 for Children/Young Adults?

FEATURING Josep-Maria Ribera
  • 85 views
  • December 22, 2020
16:49

2nd SOHO Italian Conference

2020 SOHO Updates on ALL: Does Ponatinib+Steroids Help Induce CHR in Ph+ Elderly/Unfit Patients? Is Inotuzumab Effective in Obtaining MRD Negativity?

FEATURING Giovanni Martinelli
  • 138 views
  • December 22, 2020
  • 1
11:57

2nd SOHO Italian Conference

2020 SOHO Updates on Newly Diagnosed AML: Does CPX-351 Increase OS and CR vs. Conventional Chemo? Can We Use It for Both Induction and Consolidation? Is It Beneficial for FLT3-Mutated Patients?

FEATURING Claudio Cerchione
  • 97 views
  • December 22, 2020
  • 1
10:44

2nd SOHO Italian Conference

2020 SOHO Updates on AML: Is Targeting CAMDR a New Frontier? Can E-Selectin Antagonist Uproleselan Enhance Chemo Response?

FEATURING Claudio Cerchione
  • 90 views
  • December 22, 2020
  • 1
18:18

2nd SOHO Italian Conference

MD Anderson State of the Art in CLL Treatment: What Is Changing and What Is Staying the Same When Choosing Therapy?

FEATURING Alessandra Ferrajoli
  • 168 views
  • December 22, 2020
10:10

2nd SOHO Italian Conference

2020 SOHO Updates on Newly Diagnosed AML: What Is the ORR With Aza vs. Intensive Chemo for 70+ y/o Adults? Is Decitabine Beneficial for OS? Does Mido+Intensive Chemo Help Achieve CR in FLT3-Mutated Disease?

FEATURING Adolfo de la Fuente
  • 37 views
  • December 22, 2020
  • 1
16:49

2nd SOHO Italian Conference

2020 SOHO Update on Ph-Like ALL: How Important Are Genomic Alterations? Do Blinatumomab and Inotuzumab Work Agnostic to Ph-Like Status? What Is the Role of allo-SCT?

FEATURING Marina Konopleva
  • 17 views
  • December 8, 2020
19:30

2nd SOHO Italian Conference

2020 SOHO Update on AML in Older Patients at MD Anderson: Therapy Intensity, Maintenance Therapy, TP53-Mutated AML, Secondary AML

FEATURING Tapan Kadia
  • 191 views
  • December 7, 2020
22:54

2nd SOHO Italian Conference

2020 SOHO Update on MPN: Ruxolitinib vs. BAT in ET, Ruxolitinib in PV, Alternative Ruxolitinib Dosing & Fedratinib After Ruxolitinib in MF

FEATURING Srdan Verstovsek
  • 24 views
  • December 7, 2020
18:07

2nd SOHO Italian Conference

2020 SOHO Update on Diagnostic Approaches to Ph-Like B-ALL: CRLF2 Detection by Flow Cytometry, Fluorescence In Situ Hybridization, NGS, FISH Testing Algorithms

FEATURING Sergej Konoplev
  • 10 views
  • December 7, 2020
09:51

2nd SOHO Italian Conference

2020 SOHO Update on FLT3+ AML: What Are the Novel FLT3 Inhibitors? How Do We Overcome FLT3 Resistance to Venetoclax?

FEATURING Naval Daver
  • 60 views
  • December 7, 2020
14:15

2nd SOHO Italian Conference

2020 SOHO Update on Immunotherapy in AML: Gemtuzumab Ozogamicin Plus 7+3 vs. 7+3, CD123-Targeting ADC IMGN632 & Azacitidine + Nivolumab in R/R AML, Anti-CD47 Antibody Magrolimab + Azacitidine

FEATURING Naval Daver
  • 122 views
  • December 7, 2020
  • 1
16:36

2nd SOHO Italian Conference

How I Manage CML at MD Anderson in 2020: How Effective & Safe Is Dasatinib 50mg Daily vs. 100mg? What Is the Optimal Dasatinib + Venetoclax Dosage?

FEATURING Elias Jabbour
  • 18 views
  • December 3, 2020
13:05

2nd SOHO Italian Conference

2020 SOHO Update on Frontline Therapy Optimization in ALL: How Effective Are Ponatinib/Blinatumomab, Bcl-2 / Bcl-xL Inhibitors, and CAR-T in Adults/Elderly?

FEATURING Elias Jabbour
  • 19 views
  • December 3, 2020
10:43

2nd SOHO Italian Conference

2020 SOHO Update on Frontline MDS: What Is the Role of Genomic Annotation? What Are the New Combinations and Ways to Deliver HMAs?

FEATURING Guillermo Garcia-Manero
  • 13 views
  • December 3, 2020
12:20

2nd SOHO Italian Conference

2020 SOHO Update on Antibodies in AML: Is Gemtuzumab Ozogamicin Effective in ND / CD33 AML? Is There Activity With Bispecific Antibodies? What Role Do These Agents Have in MRD Clearance?

FEATURING Farhad Ravandi
  • 15 views
  • December 3, 2020
12:54

2nd SOHO Italian Conference

2020 SOHO Update on Maintenance AML: Does It Improve Clinical Outcome? Can We Consider MRD Assessment as a Surrogate for Outcome?

FEATURING Farhad Ravandi
  • 15 views
  • December 3, 2020